Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.500-4.500 for the period, compared to the consensus earnings per share estimate of 4.440. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.39 during midday trading on Friday, reaching $86.96. The company had a trading volume of 523,063 shares, compared to its average volume of 288,972. The business has a 50-day moving average of $79.19 and a two-hundred day moving average of $75.34. The company has a market cap of $4.30 billion, a P/E ratio of 20.37, a P/E/G ratio of 2.43 and a beta of 0.50. The company has a quick ratio of 2.10, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 1 year low of $60.00 and a 1 year high of $88.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities research analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Canaccord Genuity Group lifted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday. Finally, DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $92.50.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 in the last three months. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.